Reviewing Gilead's formidable 2015: A year marked by higher sales and new criticism

The biotech giant's sales continued to chug along in the midst of an industry-wide controversy over high drug prices. We examined the company's performance last year—and what it tells us about what to expect in 2016.

By Ned Pagliarulo • Jan. 22, 2016

Glaxo, Qualcomm reportedly mulling med tech joint venture

The partnership between the two companies could be worth up to $1 billion for the development of medical technology, according to reports from Bloomberg and FT.

By Nicole Gray • Jan. 21, 2016

Express Scripts shares rocked by antitrust suit, Anthem breakup threat

The PBM giant has been on a downward slide since Anthem's CEO's statements at the JPMorgan Healthcare conference last week. And now, it's being sued by six compounding pharmacies.

By Nicole Gray • Jan. 20, 2016

Biotech Acorda buys Finnish firm Biotie & its Parkinson's candidates for $363M

The acquisition gives Acorda Therapeutics access to two drugs for the treatment of Parkinson's disease, one of which is in a Phase 3 trial. 

By Ned Pagliarulo • Jan. 19, 2016

Analysts skeptical about Shire's Baxalta 'growth play' strategy

There are concerns the $500 million in cost-savings projected by Shire from its Baxalta buyout is too low. But CEO Flemming Ornskov says his company can beat the odds with strong portfolios.

By Nicole Gray • Jan. 14, 2016

ASCO: Reform the 'clinical pathways' approach to cancer

The American Society for Clinical Oncology (ASCO) this week released new policy recommending the 'clinical pathways' approach be made more transparent and consistent. 

By Nicole Gray • Jan. 14, 2016

More from JPM16: Glaxo talks potential spinoff, 'Pfallergan' addresses future breakup scenario

Several pharma giants discussed major elements of their corporate structures on Tuesday. And Pfizer CEO Ian Read promised the firm would get it right the second time around on cancer immunotherapies.

By Sy Mukherjee • Jan. 13, 2016

JPM16: An unprecedented cancer cure 'MoonShot,' Anthem threatens Express Scripts breakup

One of the boldest partnership and research efforts to be announced out of the JPMorgan Healthcare Conference so far also received a prime time boost from President Barack Obama's final State of the Union address on Tuesday night.

By Sy Mukherjee • Jan. 13, 2016

Allergan acquires Anterios to enhance neurotoxin delivery, bolsters Botox portfolio

Anterios' platform enables Botox and other neurotoxins to be delivered through the skin, rather than by injection. 

By Nicole Gray • Jan. 12, 2016

Seres signs on with Nestlé Health Science in gut drug partnership

The deal will make Nestlé Health Science the main partner for Seres outside of North America. 

By Nicole Gray • Jan. 12, 2016

Walgreens' leadership defends unconventional Valeant deal

Walgreens' CEO expects the agreement with Valeant will help lower costs, comparing it to successful arrangements with pharmacies in Europe. 

By Nicole Gray • Jan. 11, 2016

Shire buys Baxalta for $32 billion, ending months-long pursuit

After rejecting prior offers, Baxalta agreed to a stock and cash deal. Ireland-based Shire will gain Baxalta's hemophilia and rare-disease drug portfolio. 

By Ned Pagliarulo • Jan. 11, 2016

Biotech Moderna partners with CRO to advance promising RNA therapies into trials

Since 2012, Moderna has raised $1 billion in venture funding for messenger RNA therapies. However, it has not yet tested any candidates in clinical trials. 

By Nicole Gray • Jan. 11, 2016

Deal-hungry J&J partners with Chinese firm to focus on hep B breakthrough

Johnson & Johnson (J&J) is revealing details of 21 partnerships at this year's JP Morgan meeting. 

By Nicole Gray • Jan. 8, 2016

Flurry of venture deals hits biopharma ahead of JPMorgan healthcare conference

J&J, Roche, Amgen Ventures, and Abbvie have all stepped into new collaborations with several venture biopharma firms.

By Ned Pagliarulo • Jan. 7, 2016

In efficiency bid, Novartis selling Alcon unit to Recipharm in $20M deal

Recipharm will expand its presence in France—one of its seven key operational regions. 

By Nicole Gray • Jan. 7, 2016

Biogen partners with Rodin on Alzheimer's research, possible buy-out opp

Under the terms of the deal, Biogen has the right to acquire Rodin for $485 million. 

By Nicole Gray • Jan. 7, 2016

Major Chinese pharma firm plots a $3 billion IPO in Hong Kong

The IPO could happen sometime in the third quarter, and would be the largest healthcare IPO on Hong Kong's exchange. 

By Nicole Gray • Jan. 5, 2016

Baxalta strikes a $1.6B immuno-oncology deal ahead of potential Shire deal

The deal with Symphogen covers six early-stage drugs. 

By Nicole Gray • Jan. 5, 2016

WellCare ditches UnitedHealth in PBM scuffle, opts for CVS

The switch became effective on January 1, shifting WellCare's 3.8 million members onto CVS Health Corp's network. 

By Nicole Gray • Jan. 4, 2016

The year ahead: 11 execs & experts predict what's in store for biopharma in 2016

With a record-setting year behind us, we can only imagine what’s ahead for the industry in the coming months. Fortunately, industry execs and experts from Sanofi, Boehringer, Bain, amfAR, Novocure, and others shared some of their own predictions with BioPharma Dive.

By Nicole Gray • Jan. 4, 2016

In unique Valeant-Walgreens distribution deal, drugmaker to retain titles to its therapies

As part of the deal, Valeant will take a $150 million revenue hit. 

By Nicole Gray • Dec. 23, 2015

Baxalta fielding buyout offers, but may land with Shire after all

Shire has renewed its push to acquire Baxalta, adding cash into a previous all-stock offer, according to Reuters. 

By Nicole Gray • Dec. 23, 2015

11 biopharma execs & experts look back on 2015: A record year for record-breaking

We spoke with bigwigs from Sanofi, the Biosimilars Council, Novocure, Accenture, Bain, amfAR, Boehringer Ingelheim, and more on what they considered the most significant events that drove biopharma this past year.

By Nicole Gray • Dec. 22, 2015

Bayer pumping 335 million euros into CRISPR Therapeutics gene-editing partnership

Bayer plans to research how to bring the gene-editing mechanism to target cells. 

By Nicole Gray • Dec. 22, 2015